World's Best Scientists 2026 revealed!

D-Index & Metrics

Medicine

D-Index
93
Citations
40184
World Ranking
10736
National Ranking
5520

Overview

Alexander Drilon is affiliated with Memorial Sloan Kettering Cancer Center in the United States and has contributed extensively to oncology and related biomedical fields. Their research encompasses both clinical and molecular aspects of cancer, with a particular focus on genetic mutations and targeted treatments.

The main fields of study in Drilon's work include:

  • Medicine
  • Biochemistry, Genetics and Molecular Biology

The subfields emphasize specialization areas such as:

  • Pulmonary and Respiratory Medicine
  • Oncology
  • Cancer Research
  • Molecular Biology
  • Genetics

Drilon's research addresses multiple core topics, notably:

  • Lung Cancer Treatments and Mutations
  • Cancer Genomics and Diagnostics
  • Colorectal Cancer Treatments and Studies
  • Lung Cancer Research Studies
  • Glioma Diagnosis and Treatment
  • Cholangiocarcinoma and Gallbladder Cancer Studies
  • Cancer Immunotherapy and Biomarkers

Frequent co-authors in collaborative efforts include:

  • W. Marston Linehan
  • David S. Hong
  • Marc Ladanyi
  • Theodore W. Laetsch
  • Shivaani Kummar

Key publication venues where Drilon's work appears regularly are:

  • Journal of Clinical Oncology
  • Annals of Oncology
  • Journal of Thoracic Oncology
  • Cancer Research
  • Clinical Cancer Research

Representative recent scientific papers authored or co-authored by Drilon include:

  • "Larotrectinib in patients with TRK fusion-positive solid tumours: a pooled analysis of three phase 1/2 clinical trials" (2020, The Lancet Oncology)
  • "Efficacy of Selpercatinib in RET Fusion-Positive Non-Small-Cell Lung Cancer" (2020, New England Journal of Medicine)
  • "Efficacy of Selpercatinib in RET -Altered Thyroid Cancers" (2020, New England Journal of Medicine)
  • "Tumour-agnostic efficacy and safety of selpercatinib in patients with RET fusion-positive solid tumours other than lung or thyroid tumours (LIBRETTO-001): a phase 1/2, open-label, basket trial" (2022, The Lancet Oncology)
  • "Antitumor activity of crizotinib in lung cancers harboring a MET exon 14 alteration" (2020, Nature Medicine)

These publications highlight Drilon's involvement in trials and studies focusing on targeted therapies for cancers with specific genetic alterations, reflecting integration of clinical oncology and molecular biology.

Best Publications

  • Efficacy of Larotrectinib in TRK Fusion–Positive Cancers in Adults and Children

    Alexander Drilon;Theodore W. Laetsch;Shivaani Kummar;Steven G. DuBois

  • Entrectinib in patients with advanced or metastatic NTRK fusion-positive solid tumours: integrated analysis of three phase 1–2 trials

    Robert C Doebele;Alexander Drilon;Alexander Drilon;Luis Paz-Ares;Salvatore Siena

  • NTRK fusion-positive cancers and TRK inhibitor therapy

    Emiliano Cocco;Maurizio Scaltriti;Alexander Drilon

  • Immune checkpoint inhibitors for patients with advanced lung cancer and oncogenic driver alterations: results from the IMMUNOTARGET registry

    J. Mazieres;A. Drilon;A. Lusque;L. Mhanna

  • Larotrectinib in patients with TRK fusion-positive solid tumours: a pooled analysis of three phase 1/2 clinical trials

    David S Hong;Steven G DuBois;Shivaani Kummar;Anna F Farago

  • Safety and Antitumor Activity of the Multitargeted Pan-TRK, ROS1, and ALK Inhibitor Entrectinib: Combined Results from Two Phase I Trials (ALKA-372-001 and STARTRK-1).

    Alexander Drilon;Salvatore Siena;Sai Hong Ignatius Ou;Manish Patel

  • HER kinase inhibition in patients with HER2- and HER3-mutant cancers.

    David M. Hyman;Sarina A. Piha-Paul;Helen Won;Jordi Rodon

  • Efficacy of Selpercatinib in RET Fusion–Positive Non–Small-Cell Lung Cancer

    Alexander Drilon;Geoffrey R. Oxnard;Daniel S.W. Tan;Herbert H.F. Loong

  • Efficacy of Selpercatinib in RET-Altered Thyroid Cancers

    Lori J Wirth;Eric Sherman;Bruce Robinson;Benjamin Solomon

  • Response to MET Inhibitors in Patients with Stage IV Lung Adenocarcinomas Harboring MET Mutations Causing Exon 14 Skipping

    Paul K. Paik;Paul K. Paik;Alexander Drilon;Alexander Drilon;Pang Dian Fan;Helena Yu;Helena Yu

  • Prospective Comprehensive Molecular Characterization of Lung Adenocarcinomas for Efficient Patient Matching to Approved and Emerging Therapies.

    Emmet J. Jordan;Hyunjae R. Kim;Maria E. Arcila;David Barron

  • Response to Cabozantinib in Patients with RET Fusion-Positive Lung Adenocarcinomas

    Alexander Drilon;Lu Wang;Adnan Hasanovic;Yoshiyuki Suehara

  • Five-Year Survival and Correlates among Patients with Advanced Melanoma, Renal Cell Carcinoma, or Non-Small Cell Lung Cancer Treated with Nivolumab

    Suzanne L. Topalian;F. Stephen Hodi;Julie R. Brahmer;Scott N. Gettinger

  • Repotrectinib (TPX-0005) Is a Next-Generation ROS1/TRK/ALK Inhibitor That Potently Inhibits ROS1/TRK/ALK Solvent- Front Mutations

    Alexander Drilon;Sai Hong Ignatius Ou;Byoung Chul Cho;Dong Wan Kim

  • NTRK fusion detection across multiple assays and 33,997 cases: diagnostic implications and pitfalls

    James P. Solomon;Irina Linkov;Andrea Rosado;Kerry Mullaney

  • Ado-Trastuzumab Emtansine for Patients With HER2-Mutant Lung Cancers: Results From a Phase II Basket Trial

    Bob T. Li;Ronglai Shen;Darren Buonocore;Zachary T. Olah

  • Cabozantinib in patients with advanced RET-rearranged non-small-cell lung cancer: an open-label, single-centre, phase 2, single-arm trial

    Alexander Drilon;Natasha Rekhtman;Maria Arcila;Lu Wang

  • Next-Generation Sequencing of Pulmonary Large Cell Neuroendocrine Carcinoma Reveals Small Cell Carcinoma–like and Non–Small Cell Carcinoma–like Subsets

    Natasha Rekhtman;Maria C. Pietanza;Matthew D. Hellmann;Jarushka Naidoo

  • Pan-Trk Immunohistochemistry Is an Efficient and Reliable Screen for the Detection of NTRK Fusions.

    Jaclyn F. Hechtman;Ryma Benayed;David M. Hyman;Alexander Drilon

  • Entrectinib in ROS1 fusion-positive non-small-cell lung cancer: integrated analysis of three phase 1-2 trials.

    Alexander Drilon;Alexander Drilon;Salvatore Siena;Rafal Dziadziuszko;Fabrice Barlesi

Frequent Co-Authors

David M. Hyman
David M. Hyman Memorial Sloan Kettering Cancer Center
Mark G. Kris
Mark G. Kris Memorial Sloan Kettering Cancer Center
Marc Ladanyi
Marc Ladanyi Memorial Sloan Kettering Cancer Center
Maria E. Arcila
Maria E. Arcila Memorial Sloan Kettering Cancer Center
Charles M. Rudin
Charles M. Rudin Memorial Sloan Kettering Cancer Center
Gregory J. Riely
Gregory J. Riely Memorial Sloan Kettering Cancer Center
Michael F. Berger
Michael F. Berger Memorial Sloan Kettering Cancer Center
Natasha Rekhtman
Natasha Rekhtman Memorial Sloan Kettering Cancer Center
Robert C. Doebele
Robert C. Doebele University of Colorado Denver
David S. Hong
David S. Hong The University of Texas MD Anderson Cancer Center

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

If you’re exploring alternatives to a traditional MD degree, there are many online programs that can prepare you for rewarding careers in healthcare. For example, nursing is a popular pathway with a range of entry points. Some prospective students look for the easiest bsn program to get into to streamline their application process and start their nursing career sooner.

Those looking to avoid standardized admissions tests might also be interested in a nursing school that does not require teas test. This can make nursing more accessible for dedicated students who may struggle with high-stakes exams.

Not everyone in healthcare works directly with patients. Administrative and specialist roles are also in demand. You can pursue healthcare management through the best online healthcare administration degree programs. For those drawn to medical records or insurance, generous financial aid for medical billing and coding is available at many accredited schools.

By considering these diverse pathways, you can find flexible, reputable online education options that match your healthcare career ambitions.

Best Scientists Citing Alexander Drilon

Trending Scientists

Recently Published Articles